MAIA BIOTECHNOLOGY INC (MAIA) Stock News
NYSEARCA:MAIA - NYSE Arca - US5526411021 - Common Stock - Currency: USD
MAIA Latest News, Press Relases and Analysis
CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000
MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
MAIA Biotechnology Announces Director Participation in Recent Private Placement
Best Momentum Stocks to Buy for May 6th
MAIA, BYRN and OCX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 6, 2025.
New Strong Buy Stocks for May 6th
MAIA, BYRN, OCX, BBVA and HMY have been added to the Zacks Rank #1 (Strong Buy) List on May 6, 2025.
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q2 2024
MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the second quarter of 2024.
CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement
MAIA Biotechnology Announces $1.08 Million Private Placement
MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders
Is Alight, Inc. (ALIT) About to Explode?
We recently compiled a list of the 12 Stocks That Are About to Explode. In this article, we are going to take a look at where Alight, Inc. (NYSE:ALIT) stands against the other stocks that are about to explode. Despite the current headwinds and uncertainty (which also caused heightened volatility in the last 2 weeks), […]
Best gold ETFs: Top funds for investing in gold
Many investors turn to gold-backed ETFs to help diversify their portfolio and hedge against inflation.
MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know
MAIA Biotechnology, Inc. (MAIA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug
MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million
MAIA Biotechnology Announces Private Placement of $2,715,000
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology to Present at Biotech Showcase 2025
MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications
MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
MAIA Biotechnology Announces Private Placement of Approximately $950,000
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement
MAIA Biotechnology Announces $2.44 Million Private Placement
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics
MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NSCLC patients. Results include a 38% ORR, 85% DCR, and lower toxicity, with six patients continuing treatment beyond 12 months.
Mentions: REGN
